Jefferies Raises Price Target on SodaStream (SODA) Following 1Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Jefferies Raises Price Target on SodaStream (SODA) Following 1Q Results
May 10, 2016 12:50 PM EDT
EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) 55.1% LOWER; announced reprioritization of the companys pipeline to focus exclusively on developing biosimilars for the treatment of rare diseases. This includes reallocating the Companys resources to focus on the development of BOW080 (eculizumab; reference biologic Soliris®) for the potential treatment of ultra-rare blood disorders and BOW070 (tocilizumab; reference biologic Actemra) for the potential treatment of an uncommon lymphoproliferative disorder known as Castlemans disease.
ChemoCentryx, Inc. (Nasdaq: CCXI) 41.0% HIGHER; Vifor Pharmaand and... More
May 10, 2016 9:36 AM EDT
Today's pre-open stock movers:
ChemoCentryx, Inc. (Nasdaq: CCXI) 78.6% HIGHER; Vifor Pharma, a company of the Galenica Group, and ChemoCentryx, Inc. (Nasdaq:... More
May 10, 2016 8:14 AM EDT
SodaStream (NASDAQ: SODA) reported Q1 EPS of $0.29, $0.18 better than the analyst estimate of $0.11. Revenue for the quarter came in at $100.9 million versus the consensus estimate of $89 million.
"Our first quarter results demonstrate that our growth plan, which centers on repositioning the SodaStream brand around... More
